Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Shared on 30 Oct 25

Fair value Decreased 8.11%

Analysts have adjusted their price target for Akebia Therapeutics from $7.40 to $6.80. They cite slight shifts in projected valuation metrics and underlying financial assumptions.

Shared on 01 May 25

AKBA: Expanding Access in Dialysis Settings Will Drive Future Upside

Shared on 30 Oct 25

Expanding Dialysis Access Will Unlock New CKD Treatment Frontiers